Long Noncoding RNA UC-173 Enhances Gut Barrier Function by Promoting Translation of Tight Junction Claudin-1

usual care.Conversely, for a biomarker that costs $253, a 96.7% accuracy is required to remain cost-saving.Above $253, the biomarker-based approach is no longer cost-saving vs. usual care, even when the test is 100% accurate at detecting IBS-D.Conclusion: These results can guide investigators as they develop, validate, and price IBS-D biomarkers for use in everyday clinical practice.Based on the natural history and usual costs of care for IBS-D, any biomarker exceeding $253, regardless of diagnostic accuracy, will not be cost-saving.However, future analyses should also evaluate cost per quality-adjusted life year (QALY) gained to explore the balance between biomarker cost and QALY benefits from more accurate testing.TABLE.Base-case probability and cost estimates used in the decision model. FIGURE.Biomarker accuracy required for the IBS-D biomarker-based approach to be costsaving vs. usual care, according to biomarker cost.We calculated accuracy through the following equation: biomarker sensitivity x IBS prevalence among Rome IV positive individuals + biomarker specificity x (1 -IBS prevalence among Rome IV positive individuals).